Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy
    Meeting Abstract

    Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update
    Meeting Abstract

    Rea, D.; Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J.; Cortes, J. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms
    Meeting Abstract

    Rampal, R.; Ramanathan, S.; Papayannidis, C.; von Bubnoff, N.; Díaz, M. D. T.; Vidriales, M. B.; Burguera, A. D. L. F.; Masarova, L.; Al-Ali, H. K.; Lavie, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653)
    Meeting Abstract

    Ponce, D. M.; Lombardo, M. J.; Ford, C. B.; Peled, J. U.; Van Den Brink, M. R. M.; Tejura, B.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Patel, K.; Sano, D.; Maris, M.; Lesokhin, A. M.; Von Keudell, G.; Doucette, K.; Ramchandren, R.; Pavlov, D.; Uger, R. A.; Molloy, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma
    Meeting Abstract

    Patel, K.; Orlowski, R. Z.; Doucette, K.; Maris, M.; Pianko, M. J.; Ramchandren, R.; Stevens, D. A.; Vesole, D. H.; Uger, R. A.; Scheuber, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Rocafiguera, A. O.; Nooka, A. K.; Rosiñol, L.; Bahlis, N. J.; Rodríguez-Otero, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results
    Meeting Abstract

    Mims, A. S.; Huang, Y.; Eisenmann, E.; Buelow, D.; Swords, R. T.; Foster, M. C.; Lin, T. L.; Baer, M. R.; Kovacsovics, T.; Al-Mansour, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save